CytoDyn has withdrawn an approval application for leronlimab in a specific HIV indication, the latest installment in the troubled biotech’s ongoing saga to get the monoclonal antibody to market.

Please provide your email address to receive an email when new articles are posted on . CORD has submitted a premarket approval application to the FDA for the Model SC9 IOL to treat patients with ...

ALBUQUERQUE, N.M., March 26, 2025 /PRNewswire/ -- TNMP, the wholly-owned Texas subsidiary of TXNM Energy, Inc. (NYSE: TXNM) received approval from the Public Utility Commission of Texas (PUCT) for its ...

Darzalex Faspro's FDA application targets high-risk smoldering multiple myeloma, a precursor to active multiple myeloma with no current approved treatments. The phase 3 AQUILA study supports the ...

Anavex (AVXL) has submitted an MAA for blarcamesine in Alzheimer's, a critical step that puts their molecule under regulatory scrutiny. Despite past trial failures, Anavex's Phase 2b/3 trial showed ...

The EU recommends Anavex proceed with a full approval application for Alzheimer's drug Blarcamesine based on full Phase 2b/3 trial data. The U.S. FDA may grant accelerated approval to Anavex's ...

Discover how pre-approved credit offers affect your credit score, including the difference between soft and hard inquiries ...